Erken dönemde dantrolen ile tedavi edilen malign hipertermi

Malignant hyperthermia (MH) is a rare, but life-threatening, autosomal dominant pharmacogenetic disorder triggered by exposure to volatile anesthetics and/or depolarizing muscle relaxants. The key diagnostic features include an unexplained elevation of expired carbondioxide, muscle rigidity, rhabdomyolysis, hyperthermia, acidosis and hyperkalemia. Given the potential fatal outcome of MH, treatment with dantrolene should be initiated once the diagnosis is suspected. Dantrolene sodium is a specific antagonist of the pathophysiologic changes of MH and should be available wherever general anesthesia is administered. In this case report, we present a 32-year-old male patient in whom MH was suspected while providing maintenance of anesthesia with sevoflurane. The patient responded to the Dantrolene treatment. Complications or recurrence of MH was not observed postoperatively. We want to emphasize that the efficacy of dantrolene treatment in the management of malignant hyperthermia and therefore it can be accessed in case of emergency, as a life-saving agent.